Tumor- and stromal cell-specific expression of topoisomerase IIα and HER-2/neu in primary and recurrent ovarian cancer: Results of a prospective study

  • Authors:
    • Radoslav Chekerov
    • Dominique Koensgen
    • Irina Klaman
    • André Rosenthal
    • Guelten Oskay-Oezcelik
    • Alexander Mustea
    • Werner Lightenegger
    • Edgar Dahl
    • Jalid Sehouli
  • View Affiliations

  • Published online on: November 1, 2009     https://doi.org/10.3892/mmr_00000207
  • Pages: 1011-1016
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to evaluate the expression of topoisomerase IIα (TOP2A) and HER-2 in tumor epithelial and adjacent stromal cells in ovarian cancer (OvCa). Immunohistochemistry for TOP2A and HER-2 was performed on 50 OvCa specimens from the Tumor Bank of Ovarian Cancer, and was correlated to established clinicopathological parameters. TOP2A was expressed in 98% and HER-2 in 52% of the OvCa specimens. Moderate expression of TOP2A was detected in 72% of the adjacent stromal cells. TOP2A and HER-2 were strongly expressed in the tumor epithelial cells of primary OvCa, but reduced in recurrent OvCa. Stromal expression of TOP2A increased in recurrent OvCa after platinum-based chemotherapy. In conclusion, distinct epithelial and stromal cell expression of TOP2A and HER-2 is a novel feature in the tumor biology of OvCa. Differential cellular expression of TOP2A in relation to previous chemotherapy probably reflects a modified activity of the ‘stromal compartment’ in drug resistance. Thus, analysis of TOP2A expression in tumor and stromal OvCa cells can aid in identifying subgroups of patients who may have a more favorable response to chemotherapy.

Related Articles

Journal Cover

November-December 2009
Volume 2 Issue 6

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Chekerov R, Koensgen D, Klaman I, Rosenthal A, Oskay-Oezcelik G, Mustea A, Lightenegger W, Dahl E and Sehouli J: Tumor- and stromal cell-specific expression of topoisomerase IIα and HER-2/neu in primary and recurrent ovarian cancer: Results of a prospective study. Mol Med Rep 2: 1011-1016, 2009.
APA
Chekerov, R., Koensgen, D., Klaman, I., Rosenthal, A., Oskay-Oezcelik, G., Mustea, A. ... Sehouli, J. (2009). Tumor- and stromal cell-specific expression of topoisomerase IIα and HER-2/neu in primary and recurrent ovarian cancer: Results of a prospective study. Molecular Medicine Reports, 2, 1011-1016. https://doi.org/10.3892/mmr_00000207
MLA
Chekerov, R., Koensgen, D., Klaman, I., Rosenthal, A., Oskay-Oezcelik, G., Mustea, A., Lightenegger, W., Dahl, E., Sehouli, J."Tumor- and stromal cell-specific expression of topoisomerase IIα and HER-2/neu in primary and recurrent ovarian cancer: Results of a prospective study". Molecular Medicine Reports 2.6 (2009): 1011-1016.
Chicago
Chekerov, R., Koensgen, D., Klaman, I., Rosenthal, A., Oskay-Oezcelik, G., Mustea, A., Lightenegger, W., Dahl, E., Sehouli, J."Tumor- and stromal cell-specific expression of topoisomerase IIα and HER-2/neu in primary and recurrent ovarian cancer: Results of a prospective study". Molecular Medicine Reports 2, no. 6 (2009): 1011-1016. https://doi.org/10.3892/mmr_00000207